You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

extranodal natural killer/T-cell lymphoma

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Extranodal Natural Killer T Cell Lymphoma Trial in China (Tislelizumab combined with Liposomal mitoxantrone HCl, Maintenance of

Recruiting
  • Extranodal Natural Killer T Cell Lymphoma
  • Tislelizumab combined with Liposomal mitoxantrone hydrochloride
  • Maintenance of tislelizumab
  • Beijing, China
  • +5 more
Jul 15, 2022

Extranodal NK/T-cell Lymphoma Trial in Houston (sugemalimab)

Available
  • Extranodal NK/T-cell Lymphoma
  • Houston, Texas
    University of Texas MD Anderson Cancer Center
Mar 18, 2022

Lymphoma, Extranodal NK-T-Cell Trial in Seoul (avelumab)

Active, not recruiting
  • Lymphoma, Extranodal NK-T-Cell
  • Seoul, Korea, Republic of
    81, Irwon-ro, Gangnam-gu, Seoul, Republic of Korea
Sep 22, 2021

Extranodal Natural Killer/T-cell Lymphoma Trial in Nanjing (circulate free methylated EBV DNA)

Not yet recruiting
  • Extranodal Natural Killer/T-cell Lymphoma
  • circulate free methylated EBV DNA
  • Nanjing, China
    The First Affiliated Hospital of Nanjing Medical University
Apr 19, 2022

Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type, Classical Hodgkin Lymphoma Trial in Houston (CD30.CAR-EBVST cells)

Recruiting
  • Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type
  • Classical Hodgkin Lymphoma
  • CD30.CAR-EBVST cells
  • Houston, Texas
  • +1 more
Jul 20, 2022

Extranodal NK/T-cell Lymphoma, Nasal Type Trial in Shanghai (Methotrexate, Etoposide, Dexamethasone)

Active, not recruiting
  • Extranodal NK/T-cell Lymphoma, Nasal Type
  • Shanghai, Shanghai, China
    Ruijin Hospital
Aug 19, 2021

Natural Killer/T-Cell Lymphoma, Nasal and Nasal-Type, Early Stage, Anlotinib Trial in Guangzhou (Sintilimab)

Completed
  • Natural Killer/T-Cell Lymphoma, Nasal and Nasal-Type
  • +7 more
  • Guangzhou, Guangdong, China
    Sun Yat-Sen University Cancer Center
Jun 6, 2022

Natural Killer/T-Cell Lymphoma, Nasal and Nasal-Type Trial in Shanghai (tislelizumab, azacytidine, lenalidomide, tislelizumab,

Recruiting
  • Natural Killer/T-Cell Lymphoma, Nasal and Nasal-Type
  • tislelizumab, azacytidine, lenalidomide
  • tislelizumab, etoposide, pegaspargase
  • Shanghai, Shanghai, China
    Xinhua Hospital,Shanghai Jiao Tong University School of Medicine
Sep 17, 2021

Safety and Efficacy Trial in Guangzhou, Wuhan (Sintilimab, Chidamide)

Completed
  • Safety and Efficacy
  • Guangzhou, Guangdong, China
  • +3 more
Apr 6, 2022

Extranodal NK/T-cell Lymphoma, Nasal Type Trial in Guangzhou (Pegaspargase, Anti-PD-1 mAb, Definitive intensity-modulated

Not yet recruiting
  • Extranodal NK/T-cell Lymphoma, Nasal Type
  • Guangzhou, Please Select, China
    Sun Yat-sen University Cancer Center
Dec 16, 2020

Extranodal NK-T-Cell Lymphoma Trial in Seoul (Etoposide, Ifosfamide, Dexamethasone)

Unknown status
  • Extranodal NK-T-Cell Lymphoma
  • Seoul, Seoul, Korea, Republic Of, Korea, Republic of
  • +1 more
Oct 21, 2020

Natural Killer/T-Cell Lymphoma, Nasal and Nasal-Type Trial in Shanghai (Anlotinib)

Completed
  • Natural Killer/T-Cell Lymphoma, Nasal and Nasal-Type
  • Shanghai, China
    Xinhua Hospital
Sep 13, 2021

NK-T-Cell Lymphoma, Extranodal Trial in Shanghai (4 cycles of ESA regimen with sandwiched radiotherapy, 2 cycles of ESA regimen

Not yet recruiting
  • NK-T-Cell Lymphoma, Extranodal
  • 4 cycles of ESA regimen with sandwiched radiotherapy
  • +2 more
  • Shanghai, Shanghai, China
    Ruijin Hospital
Sep 29, 2023

Recurrent Adult T-Cell Leukemia/Lymphoma, Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, Refractory Adult T-Cell

Recruiting
  • Recurrent Adult T-Cell Leukemia/Lymphoma
  • +3 more
  • Columbus, Ohio
    Ohio State University Comprehensive Cancer Center
Nov 18, 2022

NK-T-Cell Lymphoma, Extranodal Trial (Pegaspargase Combined With Gemcitabine, Etoposide, Liposomal Mitoxantrone Hydrochloride

Not yet recruiting
  • NK-T-Cell Lymphoma, Extranodal
  • Pegaspargase Combined With Gemcitabine, Etoposide, Liposomal Mitoxantrone Hydrochloride and Dexamethasone (P-GEMD) regimen
  • (no location specified)
Mar 7, 2023

Extranodal NK/T-cell Lymphoma Trial (Sugemalimab, Placebo, Pegaspargase)

Not yet recruiting
  • Extranodal NK/T-cell Lymphoma
  • Sugemalimab
  • +4 more
  • (no location specified)
Jan 17, 2023

Extranodal NK/T Cell Lymphoma, Nasal Type Trial in Guangdong (IBI318(Recombinant human anti-PD1/PD-L1 bispecific antibody))

Active, not recruiting
  • Extranodal NK/T Cell Lymphoma, Nasal Type
  • IBI318(Recombinant human anti-PD1/PD-L1 bispecific antibody)
  • Guangdong, China
    Sun Yat-sen University Cancer Center
Oct 10, 2022

Peripheral T Cell Lymphoma, PTCL, Extranodal NK/T-cell Lymphoma Trial in Worldwide (Tislelizumab)

Completed
Has Results
  • Peripheral T Cell Lymphoma
  • +18 more
  • Vancouver, British Columbia, Canada
  • +29 more
Apr 29, 2022

Extranodal NK T Cell Lymphoma, NK-Cell Leukemia Trial in Xuzhou (Anti-CD56 CAR T)

Recruiting
  • Extranodal NK T Cell Lymphoma
  • NK-Cell Leukemia
  • Anti-CD56 CAR T
  • Xuzhou, Jiangsu, China
    The Affiliated Hospital of Xuzhou Medical University
Jul 10, 2023

T-cell Lymphoma, NK-Cell Lymphoma, T-cell Prolymphocytic Leukemia Trial in United States (Optional Blood Sample, Optional Nail

Recruiting
  • T-cell Lymphoma
  • +30 more
  • Optional Blood Sample
  • Optional Nail Sample
  • Duarte, California
  • +25 more
Jul 28, 2023

Lymphoma Trial (Tislelizumab)

Not yet recruiting
  • Lymphoma
  • (no location specified)
Jul 28, 2022

Extranodal NK-T-Cell Lymphoma, Nasal Type Trial in Shanghai, Urumqi (MEDA, Auto-HSCT)

Completed
  • Extranodal NK-T-Cell Lymphoma, Nasal Type
  • Shanghai, Shanghai, China
  • +6 more
Apr 24, 2020

Multiple Myeloma, Non-Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma Trial in Minneapolis (Nicotinamide Expanded Haploidentical

Completed
  • Multiple Myeloma
  • +7 more
  • Nicotinamide Expanded Haploidentical or Mismatched Related Donor Natural Killer Cells
  • Minneapolis, Minnesota
    Masonic Cancer Center, University of Minnesota
Nov 2, 2022

Extranodal NK/T-cell Lymphoma Trial in Bangkok (B-MAD chemo)

Active, not recruiting
  • Extranodal NK/T-cell Lymphoma
  • B-MAD chemotherapy
  • Bangkok, Thailand
    King Chulalongkorn Memorial Hospital
May 7, 2022

Extranodal Lymphoma or Lymphoma of Rare Pathological Types

Not yet recruiting
  • Lymphoma
  • +8 more
  • No interventions need to be specified for this study
  • Shanghai, China
    Ruijin Hospital, Shanghai Jiao Tong University School of Medicin
Jun 15, 2023